 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
566 News |  |
- |||| BMS-986179 / BMS, Opdivo (nivolumab) / BMS
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov) - May 27, 2022
P1/2, N=234, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | Trial completion date: Feb 2023 --> Oct 2021 | Trial primary completion date: Feb 2023 --> Oct 2021
- ||| BMS-986179 / BMS, Opdivo (nivolumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov) - Feb 16, 2021
P1/2, N=268, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | Trial completion date: Feb 2023 --> Oct 2021 | Trial primary completion date: Feb 2023 --> Oct 2021 Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Nov 2020 --> Feb 2023
- | BMS-986179 / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov) - Jul 28, 2019
P1/2, N=268, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Nov 2020 --> Feb 2023 Trial primary completion date: Jul 2020 --> Nov 2020
- || BMS-986179 / BMS, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov) - Feb 1, 2019
P1/2, N=221, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jul 2020 --> Nov 2020 Trial completion date: May 2020 --> Sep 2022 | Trial primary completion date: Mar 2019 --> Jul 2020
- |||| BMS-986179 / BMS, Opdivo (nivolumab) / BMS
Enrollment open, Combination therapy, PD(L)-1 Biomarker, Metastases: An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov) - Jun 27, 2016
P1/2, N=216, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: May 2020 --> Sep 2022 | Trial primary completion date: Mar 2019 --> Jul 2020 Not yet recruiting --> Recruiting
- ||| BMS-986179 / BMS, Opdivo (nivolumab) / BMS
Enrollment closed, Combination therapy, PD(L)-1 Biomarker, Metastases: An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov) - Jun 13, 2016
P1/2, N=204, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- || BMS-986179 / BMS, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov) - May 27, 2016
P1/2, N=204, Not yet recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Active, not recruiting Trial primary completion date: May 2020 --> Mar 2019
- ||||| BMS-986179 / BMS, Opdivo (nivolumab) / BMS
New P1/2 trial, Combination therapy, PD(L)-1 Biomarker, Metastases: An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov) - Apr 28, 2016
P1/2, N=204, Not yet recruiting, Sponsor: Bristol-Myers Squibb